The application of CX-4945 effectively inhibited the development of CCA and suppressed HIF-1α expression.39These findings highlight the potential of CX-4945 as a novel therapeutic agent for clinical HCC patients. The gene discussed is HIF1A; the disease is hepatocellular carcinoma.